Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma Explores Fresh Opportunity In France

Establishing Local Subsidiary Marks ‘Official Entry’ Following Supply Via Third Party

Executive Summary

Hikma has expanded its European presence by establishing a subsidiary in France, marking its “official entry” into the major market following previous supplies through a third-party partner.

You may also be interested in...



Hikma Eyes Return To Growth After Further Cutting Generics Forecasts

Hikma has once again downgraded its expectations for its generics business in 2022 as it revealed a first-half drop of 18% in sales for the unit. However, injectables and branded increases helped to offset the decline, while the company maintained that generics growth was on the horizon in 2023.

Hikma Sets Injectables Sights On France, Spain and Canada

With added steriles capacity coming online, Hikma is looking soon to expand its Injectables business unit into France and Spain. The company is also considering options for marketing injectable drugs in Canada.

Portuguese Plant Opens Up Prospects For Hikma To Expand In Europe

Extra capacity coming online at a high-containment facility in Portugal is opening up opportunities for Hikma to expand its presence in Europe’s injectables market.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151958

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel